Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Brenner Tumor 4Colorectal Neoplasms 3Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Stroke 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Lymphoid Interstitial Pneumonia 1Kidney Failure, Chronic 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 53Paclitaxel 27Carboplatin 22Brachytherapy 18Radiotherapy 17human papillomavirus vaccine, L1 type 16, 18 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Gemcitabine 12Topotecan 8Vaccines, Synthetic 7Platinum 7Papillomavirus Vaccines 7Radiation 6Bevacizumab 61,2-diaminocyclohexaneplatinum II citrate 6Neoadjuvant Therapy 5Chemotherapy, Adjuvant 5pembrolizumab 4Vinorelbine 4Radiotherapy, Intensity-Modulated 4Pemetrexed 4Drug Therapy 4Taxes 3Surgical Procedures, Operative 3Ondansetron 3Irinotecan 3Dexamethasone 3Chemoradiotherapy 3tisotumab vedotin 2specific substance maruyama 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uterine Cervical Neoplasms × Disulfides × Clear all
NCT00803062 2019-07-23

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Completed
452 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡